The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 18, 2025
Filed:
Jan. 27, 2023
Applicant:
The University of Memphis Research Foundation, Memphis, TN (US);
Inventors:
Warren O. Haggard, Memphis, TN (US);
Scott P. Noel, Memphis, TN (US);
Joel D. Bumgardner, Memphis, TN (US);
Assignee:
UNIVERSITY OF MEMPHIS RESEARCH FOUNDATION, Memphis, TN (US);
Primary Examiner:
Int. Cl.
CPC ...
C08B 31/04 (2006.01); A61K 9/70 (2006.01); A61K 31/00 (2006.01); A61K 31/7036 (2006.01); A61K 38/14 (2006.01); A61K 47/36 (2006.01); A61L 15/28 (2006.01); A61L 15/44 (2006.01); A61L 27/20 (2006.01); A61L 27/58 (2006.01); A61L 29/04 (2006.01); A61L 29/14 (2006.01); A61L 29/16 (2006.01); A61L 31/04 (2006.01); A61L 31/14 (2006.01); A61L 31/16 (2006.01); C08B 37/08 (2006.01); C08J 5/18 (2006.01); C08L 5/08 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/36 (2013.01); A61K 9/7007 (2013.01); A61K 31/00 (2013.01); A61K 31/7036 (2013.01); A61K 38/14 (2013.01); A61L 15/28 (2013.01); A61L 15/44 (2013.01); A61L 27/20 (2013.01); A61L 27/58 (2013.01); A61L 29/043 (2013.01); A61L 29/146 (2013.01); A61L 29/148 (2013.01); A61L 29/16 (2013.01); A61L 31/042 (2013.01); A61L 31/146 (2013.01); A61L 31/148 (2013.01); A61L 31/16 (2013.01); C08B 37/003 (2013.01); C08J 5/18 (2013.01); C08L 5/08 (2013.01); A61K 9/0024 (2013.01); A61L 2300/232 (2013.01); A61L 2300/25 (2013.01); A61L 2300/406 (2013.01); C08J 2305/08 (2013.01);
Abstract
The invention provides compositions featuring chitosan and methods for using such compositions for the local delivery of biologically active agents to an open fracture, complex wound or other site of infection. Advantageously, the degradation and drug elution profiles of the chitosan compositions can be tailored to the needs of particular patients at the point of care (e.g., in a surgical suite, clinic, physician's office, or other clinical setting).